Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

The levels of the serine protease HTRA1 in cerebrospinal fluid correlate with progression and disability in multiple sclerosis

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Causes of symptom dissatisfaction in patients with generalized myasthenia gravis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Diagnostic interest of whole-body MRI in early- and late-onset LAMA2 muscular dystrophies: a large international cohort

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Prediagnosis epilepsy and survival in patients with glioma: a nationwide population-based cohort study from 2009 to 2018

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Virus-specific antibody indices may supplement the total IgG index in diagnostics of multiple sclerosis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Reactivity of Rheumatoid Arthritis-Associated Citrulline-Dependent Antibodies to Epstein-Barr Virus Nuclear Antigen1-3

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Leveraging Visual Outcome Measures to Advance Therapy Development in Neuroimmunologic Disorders

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  • Simone Hjæresen
  • Tobias Sejbaek
  • Marcus Axelsson
  • Helle Vinsløv-Jensen
  • Sif Kløvedal Mortensen
  • Gorm Pihl-Jensen
  • Lenka Novakova
  • Julie Damgaard Rosgaard Christensen
  • Christian Bonde Pedersen
  • Bo Halle
  • Frantz Rom Poulsen
  • Jette Lautrup Frederiksen
  • Mengliang Zhang
  • Eirikur Benedikz
  • Jan Lycke
  • Zsolt Illes
  • Åsa Fex Svenningsen
Vis graf over relationer

BACKGROUND: High Temperature Requirement Serine Protease A1 (HTRA1) degrades extracellular matrix molecules (ECMs) and growth factors. It interacts with several proteins implicated in multiple sclerosis (MS), but has not previously been linked to the disease.

OBJECTIVE: Investigate the levels of HTRA1 in cerebrospinal fluid (CSF) in different subtypes of MS and brain tissue.

METHODS: Using ELISA, HTRA1 levels were compared in CSF from untreated patients with relapsing-remitting MS (RRMS, n = 23), secondary progressive MS (SPMS, n = 26) and healthy controls (HCs, n = 26). The effect of disease modifying therapies (DMTs) were examined in both patient groups. Cellular distribution in human brain was studied using immunochemistry and the oligointernode database, based on a single-nuclei RNA expression map.

RESULTS: HTRA1 increased in RRMS and SPMS compared to HCs. DMT decreased HTRA1 levels in both types of MS. Using ROC analysis, HTRA1 cut-offs could discriminate HCs from RRMS patients with 100% specificity and 82.6% sensitivity. In the brain, HTRA1 was expressed in glia and neurons.

CONCLUSION: HTRA1 is a promising CSF biomarker for MS correlating with disease- and disability progression. Most cell species of the normal and diseased CNS express HTRA1 and the expression pattern could reflect pathological processes involved in MS pathogenesis.

OriginalsprogEngelsk
TidsskriftJournal of Neurology
Vol/bind268
Udgave nummer9
Sider (fra-til)3316-3324
Antal sider9
ISSN0340-5354
DOI
StatusUdgivet - sep. 2021

Bibliografisk note

© 2021. Springer-Verlag GmbH, DE part of Springer Nature.

ID: 72406214